In Brief: Kensey Nash Angio-Seal
This article was originally published in The Gray Sheet
Kensey Nash Angio-Seal: Firm's puncture closure device gains FDA sign-off on early ambulation claim for use following diagnostic angiography procedures. "Clinical data which supported the change in labeling indicated significantly reduced times to ambulation with a mean of 1.4 hours for Angio-Seal patients vs. 6.6 hours for the manual pressure group," the firm says. The vascular hemostatic sealing product first received premarket approval in September 1996 ("The Gray Sheet" Oct. 7, 1996, I&W-2)...
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.